What are the core reasons why a listed company’s stock price may fall after releasing positive announcements—such as a sharp earnings increase, M&A or restructuring, or policy support?

Many investors are puzzled: when a company announces explosive earnings growth, a major merger or acquisition, or receipt of policy benefits—clearly tangible good news—the stock opens sharply lower. Most people assess 'good news' solely on its surface, overlooking the core pricing logic of China’s A-share market: stocks trade on *expectations*, not on facts that have already materialized. The moment an announcement is released is often precisely the point at which 'expectations are fulfilled'; thus, the realization of good news itself becomes a window for capital to exit. To truly understand this phenomenon, one must distinguish among expectation gaps, capital behavior, and broader market conditions—rather than simply judging price movements based on whether news appears 'positive' or 'negative'. The assumption that 'positive news must lift the stock price' is flawed. Capital markets trade in *future incremental value*, not current achievements. If the positive news has already been widely anticipated by the market, the stock may have risen well in advance; once officially announced, no new upside potential remains. 'Earnings surge = good news.' Yet many overlook critical nuances: base effects, quarter-on-quarter trends, non-recurring items, and inflection points in growth rates. For example, net profit may surge year-on-year—but primarily due to asset sales or one-time government subsidies, while core business profits actually decline; or growth slows markedly versus the prior quarter, rendering it 'positive news that falls short of expectations.' 'M&A or restructuring inevitably lifts the stock.' In reality, such deals carry substantial hidden risks: overpriced acquisitions generating massive goodwill, inflated performance commitments from targets, integration difficulties, and dilution of existing shareholders’ returns via配套 financing. Markets price in these risks directly. Another misconception is that major players deliberately suppress prices. In fact, many declines do not reflect 'washing out weak hands' by dominant players, but rather represent coordinated profit-taking by large amounts of pre-positioned capital—pure 'expectation fulfillment' behavior. The most direct trigger is expectation fulfillment—'the good news is exhausted.' Well-informed institutions and funds conduct early research and forecast announcements. Well before official disclosure, the stock price often rises steadily as expectations build. When the announcement finally goes public—and retail investors rush in en masse—early-positioned capital seizes the opportunity to sell and lock in gains. Supply-demand dynamics reverse, and the stock naturally comes under pressure. In short: 'Buy the rumor, sell the fact.' The 'good news' may contain 'quality flaws'—i.e., pseudo-positive news. Earnings growth stems from non-recurring gains, with no improvement in core operations; policy support consists only of vague official documents, lacking concrete subsidies or orders; acquisition targets possess mediocre profitability and were acquired at excessive premiums. Professional investors quickly spot such 'watered-down' positives, whereas retail investors see only headlines—leading to sharp divergence in expectations. The magnitude of the positive news falls short of the market’s consensus expectation. For instance, market rumors anticipate 100% net profit growth, yet the announcement reveals only 40%; or investors expect a major restructuring, but the deal turns out to be merely a small-scale equity stake.

Why might a stock price fall even after the release of an 'above-expectations' earnings report?

'Revenue and EPS both beat consensus, yet the stock falls' is not contradictory. The issue often lies in the lack of a unified definition of 'beat expectations.' Analysts’ consensus estimates are publicly available figures—but the stock price may already embed a *higher implicit expectation*. Before the earnings release, sell-side models may have been revised upward, and options’ implied volatility may already reflect market anticipation of significant price swings. Thus, even if results marginally exceed published consensus, they may still fall short of the threshold that triggers real investor conviction—making post-earnings pullbacks entirely normal. A second scenario: this quarter looks strong, but the outlook deteriorates. A one-off large order, a tax-rate reduction, or share repurchases shrinking the share count can all boost current-quarter EPS. Yet if management simultaneously lowers guidance for next quarter’s revenue, gross margin, or full-year free cash flow, the market shifts focus to the *revised future cash flows*. Stock prices do not reflect just the past three months—they reflect profits expected over many years ahead. A third, more subtle case: the *source* of growth deteriorates. Revenue hits target—but comes from low-margin hardware, aggressive promotions, or acquisitions; customer count grows, yet per-customer usage declines; reported profits rise, but operating cash flow is swallowed by inventory buildup, receivables, or capital expenditures.

Amgen posts higher-than-expected third quarter results, but shares dip

17 hours ago

Amgen reported third-quarter sales of $10.4 billion, beating expectations and raising its full-year outlook despite a share price dip driven by patent expirations and pipeline uncertainty regarding its weight-loss drug MariTide.

reuters

2026-11-03

Amgen posts higher-than-expected third quarter results, but shares dip

Amgen posts higher-than-expected third quarter results, but shares dip

FAQ